Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year book value per share growth
Percentile
P3
Near historical low
vs 5Y Ago
-6.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -65.97% |
| Q3 2025 | -19.11% |
| Q2 2025 | -6.23% |
| Q1 2025 | -27.27% |
| Q4 2024 | 71.15% |
| Q3 2024 | -22.13% |
| Q2 2024 | 98.11% |
| Q1 2024 | -50.81% |
| Q4 2023 | 114.83% |
| Q3 2023 | -5.35% |
| Q2 2023 | -707.82% |
| Q1 2023 | -53.62% |
| Q4 2022 | 7.34% |
| Q3 2022 | -29.94% |
| Q2 2022 | 9.57% |
| Q1 2022 | -45.07% |
| Q4 2021 | 9.61% |
| Q3 2021 | -14.44% |
| Q2 2021 | -3.86% |
| Q1 2021 | -22.02% |
| Q4 2020 | 10.48% |
| Q3 2020 | -23.87% |
| Q2 2020 | 122.38% |
| Q1 2020 | -29.99% |
| Q4 2019 | -23.85% |
| Q3 2019 | -20.03% |
| Q2 2019 | -24.33% |
| Q1 2019 | 48.12% |
| Q4 2018 | -6.57% |
| Q3 2018 | -18.77% |
| Q2 2018 | 35.35% |
| Q1 2018 | -16.79% |
| Q4 2017 | -6.41% |
| Q3 2017 | -23.74% |
| Q2 2017 | 3.68% |
| Q1 2017 | -21.33% |
| Q4 2016 | 6.26% |
| Q3 2016 | -18.48% |
| Q2 2016 | 126.34% |
| Q1 2016 | -12.20% |